Adam Enochs

Adam Enochs

Associate

Adam Enochs is an associate at Wilson Sonsini Goodrich & Rosati.

Before law school, Adam worked as a valuation analyst. He helped prepare 409A valuation reports for more than 200 privately held companies. He also worked as a financial consultant for a variety of government clients, both domestic and international.

Adam is practicing virtually in California, where he is licensed.

Experience

Adam Enochs is an associate at Wilson Sonsini Goodrich & Rosati.

Adam is practicing virtually in California, where he is licensed.

Education

J.D., University of Texas at Austin School of Law, 2022Order of the Coif
B.A., The College of William and Mary, 2015

Admissions

State Bar of California
State Bar of Texas

Credentials

Education

J.D., University of Texas at Austin School of Law, 2022Order of the Coif
B.A., The College of William and Mary, 2015

Admissions

State Bar of California
State Bar of Texas

Corporate

Recent Insights

Client Highlights

On February 29, 2024, Bakkt Holdings, Inc. (Bakkt), a leading crypto services platform, announced its entry into two securities purchase agreements relating to the purchase and sale of up to 57,670,127 shares of the company’s Class A common stock (or pre-funded warrants in lieu of Class A common stock) and accompanying warrants to purchase up to an equal number of shares of the company’s Class A common stock in concurrent registered direct offerings. The purchase price of each share of Class A common stock and accompanying warrant is $0.8670, resulting in aggregate expected gross proceeds of $50 million. Bakkt issued approximately $42.4 million of such securities on March 4, 2024, and will close on the issuance of the incremental approximately $7.6 million of such securities after the company obtains stockholder approval, subject to the satisfaction of other customary closing conditions. Wilson Sonsini Goodrich & Rosati advised Bakkt on the transaction.

Learn More

Client Highlights

On February 5, 2024, Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced the completion of a $57.7 million Series E funding round. The round was led by Fannin Partners in partnership with new and existing family/multi-family office investors. The Series E financing also included participation from returning investors including Bluebird Ventures and an undisclosed strategic investor. Wilson Sonsini Goodrich & Rosati advised lead investor Fannin Partners on the transaction.

Learn More